Moderna, Inc. (MRNA) Stock Analysis — Probabli.AI
AI-powered analysis for MRNA (Moderna, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. AI consensus: Neutral.
Last price: $54.82 · Market cap: $39.8B · AI consensus: Neutral
Moderna, Inc. is poised to benefit from its innovative mRNA platform and leadership in vaccine development, though faces challenges from competitive and regulatory fronts. Its pioneering advancements in mRNA applications beyond COVID-19 represent substantial growth opportunities. However, the market's cautious stance is understandable, given recent analyst downgrades and regulatory hurdles. The…
Probabilistic 1-Year Outlook
- Bull 3000% · Neutral 4500% · Bear 2500%
- Despite strong fundamentals like an impressive revenue growth estimate and recent earnings beat streak, the analyst consensus suggests skepticism, likely due to competitive pressures and regulatory concerns. The current…
5-Year Outlook
- Bull 4000% · Neutral 3500% · Bear 2500%
SWOT Highlights
- Strength: Leading mRNA technology platform
- Strength: Strong recent EPS beats
- Risk: High reliance on COVID-19 vaccines
- Risk: Negative current EPS estimate
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
23 Wall Street analysts rate MRNA a HOLD with a mean price target of $45.5.
Analysis generated Aug 2, 2026 · Model: gpt-4o. Run a fresh analysis on probabli.xyz/stock/MRNA.
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.